BioDelivery Sciences International (NASDAQ:BDSI) Issues Quarterly Earnings Results

BioDelivery Sciences International (NASDAQ:BDSI) released its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.34, Fidelity Earnings reports. The company had revenue of $30.31 million during the quarter, compared to analysts’ expectations of $28.86 million. BioDelivery Sciences International had a negative net margin of 34.73% and a negative return on equity of 0.85%.

Shares of BDSI traded up $0.24 during mid-day trading on Wednesday, hitting $6.09. The company’s stock had a trading volume of 197,537 shares, compared to its average volume of 893,666. The company’s 50-day moving average is $5.15 and its 200-day moving average is $4.58. BioDelivery Sciences International has a 52-week low of $2.80 and a 52-week high of $6.12. The firm has a market capitalization of $518.34 million, a price-to-earnings ratio of -8.51 and a beta of 0.39. The company has a current ratio of 2.34, a quick ratio of 2.09 and a debt-to-equity ratio of 0.88.

In other news, Director Mark A. Sirgo sold 24,506 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $4.79, for a total value of $117,383.74. Following the completion of the sale, the director now owns 1,874,637 shares of the company’s stock, valued at approximately $8,979,511.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $4.29, for a total transaction of $34,320.00. Following the completion of the sale, the director now directly owns 588,754 shares of the company’s stock, valued at approximately $2,525,754.66. The disclosure for this sale can be found here. Insiders sold a total of 373,364 shares of company stock valued at $1,859,559 in the last ninety days. Corporate insiders own 8.94% of the company’s stock.

BDSI has been the subject of several research reports. William Blair reissued a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. ValuEngine raised shares of BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 29th. BidaskClub cut shares of BioDelivery Sciences International from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of BioDelivery Sciences International in a research report on Wednesday. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. BioDelivery Sciences International presently has an average rating of “Buy” and an average price target of $6.20.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: How to identify percentage decliners

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.